CN112218633A - 包含齐多夫定和抗微生物化合物的组合 - Google Patents

包含齐多夫定和抗微生物化合物的组合 Download PDF

Info

Publication number
CN112218633A
CN112218633A CN201980029422.2A CN201980029422A CN112218633A CN 112218633 A CN112218633 A CN 112218633A CN 201980029422 A CN201980029422 A CN 201980029422A CN 112218633 A CN112218633 A CN 112218633A
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
acceptable derivative
combination
prodrug
mycobacterium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980029422.2A
Other languages
English (en)
Chinese (zh)
Inventor
A·科茨
胡彦民
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helperby Therapeutics Ltd
Original Assignee
Helperby Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helperby Therapeutics Ltd filed Critical Helperby Therapeutics Ltd
Publication of CN112218633A publication Critical patent/CN112218633A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201980029422.2A 2018-04-30 2019-04-12 包含齐多夫定和抗微生物化合物的组合 Pending CN112218633A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1807046.6 2018-04-30
GBGB1807046.6A GB201807046D0 (en) 2018-04-30 2018-04-30 Combination
PCT/GB2019/051062 WO2019211576A1 (en) 2018-04-30 2019-04-12 Combination comprising zidovudine and an antimicrobial compound

Publications (1)

Publication Number Publication Date
CN112218633A true CN112218633A (zh) 2021-01-12

Family

ID=62494998

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980029422.2A Pending CN112218633A (zh) 2018-04-30 2019-04-12 包含齐多夫定和抗微生物化合物的组合

Country Status (8)

Country Link
US (1) US11951119B2 (enExample)
EP (1) EP3787622B1 (enExample)
JP (2) JP7412008B2 (enExample)
CN (1) CN112218633A (enExample)
CA (1) CA3096575C (enExample)
GB (1) GB201807046D0 (enExample)
PL (1) PL3787622T3 (enExample)
WO (1) WO2019211576A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114196586A (zh) * 2021-12-20 2022-03-18 郑州大学 一株蒙氏肠球菌及其在发酵中草药中的应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201913068D0 (en) * 2019-09-10 2019-10-23 Helperby Therapeutics Ltd Combination

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017098274A1 (en) * 2015-12-10 2017-06-15 Helperby Therapeutic Limited Formulation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2229780T3 (es) 1998-11-09 2005-04-16 Helperby Therapeutics Limited Procesos de muestreo para identificacion de agentes antibacterianos.
US6521270B1 (en) 2001-06-11 2003-02-18 The Procter & Gamble Company Compositions comprising nitrofurantoin and uva ursi
MXPA06001552A (es) 2003-08-08 2006-09-04 Ulysses Pharmaceutical Product Quinazolinil nitrofuranos halogenados como agentes antibacterianos.
JP2005239696A (ja) 2004-01-30 2005-09-08 Daiichi Suntory Pharma Co Ltd 無機物質を配合した医薬硬質カプセル剤
WO2006021965A1 (en) * 2004-08-23 2006-03-02 Bharat Biotech International Limited Eukaryotic based synergistic formulation for gastro-intestinal disorders
US20060073173A1 (en) 2004-10-04 2006-04-06 Maria Banach Large-scale manufacturing process for the production of pharmaceutical compositions
GB201305277D0 (en) 2013-03-22 2013-05-01 Helperby Therapeutics Ltd Novel combination and use
GB201401617D0 (en) 2014-01-30 2014-03-19 Helperby Therapeutics Ltd Novel combination and use
DE102014218913A1 (de) * 2014-09-19 2016-03-24 Heraeus Medical Gmbh Verfahren zur Herstellung eines antibiotischen Polymehtylmethacrylat-Knochenzementpulvers und ein antibiotisches Polymethtylmethacrylat-Knochenzementpulver
GB201612093D0 (en) 2016-07-12 2016-08-24 Helperby Therapeutics Ltd Combination

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017098274A1 (en) * 2015-12-10 2017-06-15 Helperby Therapeutic Limited Formulation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
W A SCHWARTZM等: "Staphylococcal pyomyositis in patients infected by the human immunodeficiency virus" *
朱为敏等: "口服头孢类抗生素的研究进展" *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114196586A (zh) * 2021-12-20 2022-03-18 郑州大学 一株蒙氏肠球菌及其在发酵中草药中的应用
CN114196586B (zh) * 2021-12-20 2023-04-11 郑州大学 一株蒙氏肠球菌及其在发酵中草药中的应用

Also Published As

Publication number Publication date
JP2024009968A (ja) 2024-01-23
EP3787622C0 (en) 2023-12-13
GB201807046D0 (en) 2018-06-13
JP7412008B2 (ja) 2024-01-12
CA3096575C (en) 2025-02-04
EP3787622B1 (en) 2023-12-13
JP2021522292A (ja) 2021-08-30
PL3787622T3 (pl) 2024-05-20
CA3096575A1 (en) 2019-11-07
US20220117991A1 (en) 2022-04-21
WO2019211576A1 (en) 2019-11-07
US11951119B2 (en) 2024-04-09
JP7577376B2 (ja) 2024-11-05
EP3787622A1 (en) 2021-03-10

Similar Documents

Publication Publication Date Title
EP3099298B1 (en) Zidovudine combination therapies for treating microbial infections
JP7332155B2 (ja) ジドブジン及びカルバペネムを含む組み合わせ
JP7577376B2 (ja) ジドブジン及び抗微生物化合物を含む組み合わせ
HK1220915A1 (zh) 去甲二氢愈创木酸和氨基糖苷的组合
US20190328832A1 (en) Antimicrobial combinations
EP4045055B1 (en) Combination of zidovudine with a tetracycline antibiotic
WO2018172733A1 (en) Combinations of polymyxins
ES3036814T3 (en) Combination of zidovudine and fluoroquinolone antibiotic
US20200000742A1 (en) Combination
HK40048551A (en) Combination comprising zidovudine and an antimicrobial compound
HK40048551B (en) Combination comprising zidovudine and an antimicrobial compound
HK40001282A (en) Combination comprising zidovudine and a carbapenem
HK40001282B (en) Combination comprising zidovudine and a carbapenem
HK40079692B (en) Combination of zidovudine with a tetracycline antibiotic
HK40079692A (en) Combination of zidovudine with a tetracycline antibiotic
HK1231389B (en) Zidovudine combination therapies for treating microbial infections

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination